Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How large is the oncolytic adenovirus market, and what is its growth trajectory?
The oncolytic adenovirus market size has grown strongly in recent years. It will grow from $122.31 billion in 2024 to $132.87 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increased cancer prevalence, growing demand for targeted cancer therapies, rising R&D funding, improved delivery methods, and regulatory approvals.
The oncolytic adenovirus market size is expected to see strong growth in the next few years. It will grow to $183.22 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to growing cancer prevalence and incidence, expansion of combination therapies, regulatory advancements and approvals, technological advancements in virus engineering, and increased investment in oncology research. Major trends in the forecast period include advancements in viral engineering techniques, advanced drug delivery systems, advancements in tumor targeting precision, advanced immunotherapy combinations, and advancements in patient monitoring and diagnostics.
Get Your Free Sample of The Global Oncolytic Adenovirus Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp
What are the key forces behind the oncolytic adenovirus market’s growth in recent years?
The increasing incidence of cancer is expected to propel the growth of the oncolytic adenovirus market going forward. Cancer is a disease characterized by uncontrolled cell growth and spread to other parts of the body. The increasing incidence of cancer is driven by aging populations, lifestyle factors, environmental exposures, genetic predispositions, and improved detection. Oncolytic adenovirus targets and kills cancer cells selectively, offering a promising approach to treating the increasing incidence of cancer. For instance, in May 2024, according to the reports published by the National Cancer Institute (NCI), a US-based government agency, there were nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Furthermore, in 2023, according to the Australian Bureau of Statistics, an Australia-based government agency, 1.8% of Australians had cancer, with males (2.1%) slightly more affected than females (1.6%), especially those aged 75 and over. Therefore, the increasing incidence of cancer is driving growth in the oncolytic adenovirus market.
What are the major segments of the oncolytic adenovirus market?
The oncolytic adenovirus market covered in this report is segmented –
1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types
2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications
3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes
Subsegments:
1) By Adenovirus Type 5-Based Oncolytic Viruses: First-generation Adenovirus Type 5-based, Second-generation Adenovirus Type 5-based, Engineered Adenovirus Type 5-based
2) By Adenovirus Type 2-Based Oncolytic Viruses: First-generation Adenovirus Type 2-based, Second-generation Adenovirus Type 2-based, Engineered Adenovirus Type 2-based
3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report
Which companies dominate the oncolytic adenovirus market?
Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.
What major trends will shape the oncolytic adenovirus market during the forecast period?
Major companies operating in the oncolytic adenovirus market are focusing on combination therapies such as VCN-01, which combines oncolytic virotherapy with chemotherapy to improve tumor targeting and enhance therapeutic outcomes. VCN-01 is an oncolytic adenovirus engineered to selectively infect and destroy cancer cells while also enhancing the effectiveness of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation applies to VCN-01 when used in combination with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that targets and replicates within tumor cells, helping to break down the tumor stroma, a key obstacle to effective cancer treatment.
What are the key regional dynamics of the oncolytic adenovirus market, and which region leads in market share?
North America was the largest region in the oncolytic adenovirus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Oncolytic Adenovirus Market Report 2025 Offer?
The oncolytic adenovirus market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Oncolytic adenovirus is a genetically modified virus designed to selectively infect and destroy cancer cells while sparing healthy tissue. It replicates within tumor cells, causing them to rupture and release new viral particles, which further attack the cancer. Additionally, it stimulates the immune system to enhance the body’s anti-tumor response.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21235
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
